Literature DB >> 25944995

Murine study of portal hypertension associated endothelin-1 hypo-response.

Nicholas Theodorakis1, Mary Maluccio1, Nicholas Skill1.   

Abstract

AIM: To investigate endothelin-1 hypo-responsive associated with portal hypertension in order to improve patient treatment outcomes.
METHODS: Wild type, eNOS(-/-) and iNOS(-/-) mice received partial portal vein ligation surgery to induce portal hypertension or sham surgery. Development of portal hypertension was determined by measuring the splenic pulp pressure, abdominal aortic flow and portal systemic shunting. To measure splenic pulp pressure, a microtip pressure transducer was inserted into the spleen pulp. Abdominal aortic flow was measured by placing an ultrasonic Doppler flow probe around the abdominal aorta between the diaphragm and celiac artery. Portal systemic shunting was calculated by injection of fluorescent microspheres in to the splenic vein and determining the percentage accumulation of spheres in liver and pulmonary beds. Endothelin-1 hypo-response was evaluated by measuring the change in abdominal aortic flow in response to endothelin-1 intravenous administration. In addition, thoracic aorta endothelin-1 contraction was measured in 5 mm isolated thoracic aorta rings ex-vivo using an ADI small vessel myograph.
RESULTS: In wild type and iNOS(-/-) mice splenic pulp pressure increased from 7.5 ± 1.1 mmHg and 7.2 ± 1 mmHg to 25.4 ± 3.1 mmHg and 22 ± 4 mmHg respectively. In eNOS(-/-) mice splenic pulp pressure was increased after 1 d (P = NS), after which it decreased and by 7 d was not significantly elevated when compared to 7 d sham operated controls (6.9 ± 0.6 mmHg and 7.3 ± 0.8 mmHg respectively, P = 0.3). Abdominal aortic flow was increased by 80% and 73% in 7 d portal vein ligated wild type and iNOS when compared to shams, whereas there was no significant difference in 7 d portal vein ligated eNOS(-/-) mice when compared to shams. Endothelin-1 induced a rapid reduction in abdominal aortic blood flow in wild type, eNOS(-/-) and iNOS(-/-) sham mice (50% ± 8%, 73% ± 9% and 47% ± 9% respectively). Following portal vein ligation endothelin-1 reduction in blood flow was significantly diminished in each mouse group. Abdominal aortic flow was reduced by 19% ± 9%, 32% ± 10% and 9% ± 9% in wild type, eNOS(-/-) and iNOS(-/-) mice respectively.
CONCLUSION: Aberrant endothelin-1 response in murine portal hypertension is NOS isoform independent. Moreover, portal hypertension in the portal vein ligation model is independent of ET-1 function.

Entities:  

Keywords:  Endothelin-1; Hyper-dynamic circulation; Liver disease; Nitric oxide synthase isoforms; Portal hypertension

Mesh:

Substances:

Year:  2015        PMID: 25944995      PMCID: PMC4408454          DOI: 10.3748/wjg.v21.i16.4817

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  76 in total

1.  Enhanced G-protein-induced relaxation in portal hypertensive rats: role of nitric oxide.

Authors:  M C Hou; P A Cahill; S Zhang; E M Redmond; J V Sitzmann
Journal:  Hepatology       Date:  1997-07       Impact factor: 17.425

2.  Prostacyclin mediates splanchnic vascular response to norepinephrine in portal hypertension.

Authors:  J V Sitzmann; S S Li; P W Lin
Journal:  J Surg Res       Date:  1989-09       Impact factor: 2.192

3.  Elevated blood pressures in mice lacking endothelial nitric oxide synthase.

Authors:  E G Shesely; N Maeda; H S Kim; K M Desai; J H Krege; V E Laubach; P A Sherman; W C Sessa; O Smithies
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-12       Impact factor: 11.205

4.  Octreotide in liver cirrhosis: a salvage for variceal bleeding can be a gunshot for kidneys.

Authors:  Deniz Güney Duman; Davut Tüney; Serpil Bilsel; Fehime Benli; Sehnaz Karan; Erol Avsar; Osman Ozdogan; Nurdan Tözün
Journal:  Liver Int       Date:  2005-06       Impact factor: 5.828

5.  Role of endothelial nitric oxide synthase in the development of portal hypertension in the carbon tetrachloride-induced liver fibrosis model.

Authors:  Nicholas G Theodorakis; Yining N Wang; Jian-Ming Wu; Mary A Maluccio; James V Sitzmann; Nicholas J Skill
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-07-23       Impact factor: 4.052

6.  Octreotide for recurrent intestinal variceal bleeding in patients without portal hypertension.

Authors:  Xavier Dray; Kouroche Vahedi; Jean-Marie Odinot; Philippe Marteau
Journal:  Eur J Gastroenterol Hepatol       Date:  2009-07       Impact factor: 2.566

7.  Selective inhibition of tumor microvascular permeability by cavtratin blocks tumor progression in mice.

Authors:  Jean Philippe Gratton; Michelle I Lin; Jun Yu; Erik D Weiss; Zao Li Jiang; Todd A Fairchild; Yasuko Iwakiri; Roberto Groszmann; Kevin P Claffey; Yung Chi Cheng; William C Sessa
Journal:  Cancer Cell       Date:  2003-07       Impact factor: 31.743

8.  Effects of tumor necrosis factor, endothelin and nitric oxide on hyperdynamic circulation of rats with acute and chronic portal hypertension.

Authors:  Ji-Jian Wang; Gen-Wu Gao; Ren-Zhong Gao; Chang-An Liu; Xiong Ding; Zhen-Xiang Yao
Journal:  World J Gastroenterol       Date:  2004-03-01       Impact factor: 5.742

9.  Octreotide for esophageal variceal bleeding treated with endoscopic sclerotherapy: a randomized, placebo-controlled trial.

Authors:  G F Morales; J C Pereira Lima; A P Hornos; D L Marques; C S D Costa; L Lima Pereira; C V Lopes; R Raymondi; C A Marroni
Journal:  Hepatogastroenterology       Date:  2007 Jan-Feb

10.  Possible role for oxygen free radicals in the regulation of renal nitric oxide synthesis and blood flow.

Authors:  S I Myers; R Hernandez; A Castaneda
Journal:  Am J Surg       Date:  1995-06       Impact factor: 2.565

View more
  3 in total

1.  Crosstalk between type II NKT cells and T cells leads to spontaneous chronic inflammatory liver disease.

Authors:  Xiufang Weng; Ying He; Lavanya Visvabharathy; Chia-Min Liao; Xiaosheng Tan; Arjun Balakumar; Chyung-Ru Wang
Journal:  J Hepatol       Date:  2017-07-14       Impact factor: 25.083

2.  Shenfu Injection Promotes Vasodilation by Enhancing eNOS Activity Through the PI3K/Akt Signaling Pathway In Vitro.

Authors:  Jinqiang Zhu; Wanshan Song; Shixin Xu; Yan Ma; Baoyu Wei; Hongwu Wang; Shengyu Hua
Journal:  Front Pharmacol       Date:  2020-02-26       Impact factor: 5.810

Review 3.  Phosphodiesterases in the Liver as Potential Therapeutic Targets of Cirrhotic Portal Hypertension.

Authors:  Wolfgang Kreisel; Denise Schaffner; Adhara Lazaro; Jonel Trebicka; Irmgard Merfort; Annette Schmitt-Graeff; Peter Deibert
Journal:  Int J Mol Sci       Date:  2020-08-28       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.